A Phase IV, Multicenter, Open-Label, Single-ARM Study of The Response to Treatment After Transition to the Port Delivery System with Ranibizumab [Susvimo (Ranibizumab Injection)] in Patients with Neovascular Age-Related Macular Degeneration Previous